%0 Journal Article %1 Weller.2007 %A Weller, Michael %A Berger, Hilmar %A Hartmann, Christian %A Schramm, Johannes %A Westphal, Manfred %A Simon, Matthias %A Goldbrunner, Roland %A Krex, Dietmar %A Steinbach, Joachim P. %A Ostertag, Christoph B. %A Loeffler, Markus %A Pietsch, Torsten %A Deimling, Andreas von %D 2007 %J Clinical cancer research : an official journal of the American Association for Cancer Research %K IMISE-Publikationen %N 23 %P 6933–6937 %T Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? %V 13 %X PURPOSE The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. EXPERIMENTAL DESIGN Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation-dependent probe amplification. RESULTS After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. CONCLUSIONS Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.

@article{Weller.2007, abstract = {PURPOSE The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. EXPERIMENTAL DESIGN Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation-dependent probe amplification. RESULTS After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. CONCLUSIONS Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.}, added-at = {2014-10-15T15:04:31.000+0200}, author = {Weller, Michael and Berger, Hilmar and Hartmann, Christian and Schramm, Johannes and Westphal, Manfred and Simon, Matthias and Goldbrunner, Roland and Krex, Dietmar and Steinbach, Joachim P. and Ostertag, Christoph B. and Loeffler, Markus and Pietsch, Torsten and Deimling, Andreas von}, biburl = {https://www.bibsonomy.org/bibtex/281ae8c787eae70592e457b19bc3daef8/drtester}, interhash = {b34dd65970255b182cc7aaf21c6e8d16}, intrahash = {81ae8c787eae70592e457b19bc3daef8}, journal = {Clinical cancer research : an official journal of the American Association for Cancer Research}, keywords = {IMISE-Publikationen}, number = 23, pages = {6933–6937}, timestamp = {2014-12-03T00:09:19.000+0100}, title = {Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?}, volume = 13, year = 2007 }